These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36403965)

  • 41. PROX1 is involved in progression of rectal neuroendocrine tumors, NETs.
    Jernman J; Kallio P; Hagström J; Välimäki MJ; Haapasalo H; Alitalo K; Arola J; Haglund C
    Virchows Arch; 2015 Sep; 467(3):279-84. PubMed ID: 26063416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.
    Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D
    Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of BRAF V600E Mutation in NRAS Q61L Mutated Rectal Cancer.
    Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
    Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.
    Chen L; Liu M; Zhang Y; Guo Y; Chen MH; Chen J
    Clin Colorectal Cancer; 2021 Jun; 20(2):177-185.e13. PubMed ID: 33041225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
    Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
    Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
    Sun TY; Hendifar A; Padda SK
    Curr Oncol Rep; 2022 Jul; 24(7):819-824. PubMed ID: 35305210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients.
    Naghibalhossaini F; Hosseini HM; Mokarram P; Zamani M
    Pathol Oncol Res; 2011 Dec; 17(4):819-25. PubMed ID: 21455633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin.
    Pinheiro M; Ahlquist T; Danielsen SA; Lind GE; Veiga I; Pinto C; Costa V; Afonso L; Sousa O; Fragoso M; Santos L; Henrique R; Lopes P; Lopes C; Lothe RA; Teixeira MR
    BMC Cancer; 2010 Oct; 10():587. PubMed ID: 20979647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
    Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.
    Simbolo M; Vicentini C; Mafficini A; Fassan M; Pedron S; Corbo V; Mastracci L; Rusev B; Pedrazzani C; Landoni L; Grillo F; Cingarlini S; Rindi G; Luchini C; Scarpa A; Lawlor RT
    Virchows Arch; 2018 Dec; 473(6):709-717. PubMed ID: 30219970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
    Affolter K; Samowitz W; Tripp S; Bronner MP
    Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.
    Takane K; Matsusaka K; Ota S; Fukuyo M; Yue Y; Nishimura M; Sakai E; Matsushita K; Miyauchi H; Aburatani H; Nakatani Y; Takayama T; Matsubara H; Akagi K; Kaneda A
    Oncotarget; 2016 Dec; 7(51):84003-84016. PubMed ID: 27563825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.